Sonnet BioTherapeutics Email Format

Biotechnology ResearchNew Jersey, United States11-50 Employees

Sonnet BioTherapeutics is a Princeton, New Jersey-based biotechnology company focused on cytokine biology. Its clinical program comprises five cytokine-derived therapeutic candidates, led by SON-1010 in Phase 1 and SON-080 in Phase 1b/2a, with three additional candidates in preclinical development. The firm positions its work primarily within immune oncology, while suggesting potential applications across a broader spectrum of diseases.

The FHAB platform centers on a mechanism that binds albumin in the bloodstream to extend exposure and improve delivery of the active drug to target tissues, including tumors. Preclinical data indicate substantial improvements in both half-life and efficacy compared with non-albumin-binding cytokines, supporting the potential for combination strategies in cancer immunotherapy. In October 2024, Sonnet BioTherapeutics announced a collaboration with Alkem Laboratories to develop and commercialize SON-080 for diabetic peripheral neuropathy in India.

Get verified Sonnet BioTherapeutics emails free

Company overview Employee directory